drugset / Trial / NCT01120795
Pegylated Interferon and Ribavirin in Hepatitis C Patients on Opioid Pharmacotherapy
Phase 4
Completed
55 enrolled
Melbourne Health
Hoffmann-La Roche · collabMonash University · collabSt Vincent's Hospital, Sydney · collabThe University of New South Wales · collabWestern Hospital, Australia · collab
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to see if treatment of chronic hepatitis C in people who are on opiate replacement therapy such as methadone or buprenorphine (including patient who still inject drugs) is safe and effective.
Timeline
- Start
- 2004-02
- Primary completion
- 2006-01
- Completion
- 2006-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Peginterferon alfa-2a | Protein / enzyme biologic | 180 ug | Subcutaneous |
| Subject | Ribavirin | Small molecule | 800 mg | Oral |
| Subject | Ribavirin | Small molecule | 1000 mg | Oral |
| Subject | Ribavirin | Small molecule | 1200 mg | Oral |